Product liability bill
Senate refers S 687 to the Judiciary Committee March 2 for a period of 42 days, ending when the Senate returns from its Easter recess April 11. At that time, Judiciary must file its report, and the bill will then proceed to the Senate floor. The committee has scheduled a March 15 hearing on the product liability bill, and the Senate will recess on March 25. The Senate Commerce Committee approved S 687 on Nov. 9 ('The Pink Sheet" Nov. 15, 1993, T&G-4)
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth